palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
Published 12 days ago • 33 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
0:56
gut microbiome and treatment outcomes in hr /her2- breast cancer
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer
-
6:47
palbociclib: single-agent or in combination for the treatment of breast cancer
-
7:27
polaris: palbociclib for bipoc patients with her2-negative breast cancer
-
5:04
paloma-3: palbociclib and fulvestrant for hr-/her metastatic breast cancer
-
1:45
real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
-
8:40
the pearl study: palbociclib and endocrine therapy vs capecitabine in hr /her2- metastatic breas...
-
1:29
capitello-292: capivasertib, palbociclib, and fulvestrant for hr endocrine-resistant breast cancer
-
1:56
vepdegestrant palbociclib in er metastatic breast cancer: phase ib trial results
-
1:53
palbociclib & fulvestrant for breast cancer
-
2:29
breast cancer: palbociclib in later lines
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
2:21
palbociclib with adjuvant endocrine therapy in early breast cancer - pallas study
-
4:42
palbociclib with endocrine therapy impact on time to chemotherapy
-
13:22
palbociclib and breast cancer
-
27:44
new targeted agents in breast cancer palbociclib & beyond
-
39:21
bcfnz webinar: palbociclib (ibrance) for advanced or metastatic hr breast cancer - nz update